PBS listing is the market; private coverage is marginal for pharmaceuticals. The PBAC judges cost-effectiveness against the therapy your drug would actually replace, in a reference-pricing world where that comparator may cost very little; the pricing machinery then keeps working on your price for the life of the product.
The odds, from 521 novel EMA authorisations 2011–2020
A PBAC recommendation is necessary but not sufficient: listing follows a price negotiation, and about a quarter of recommendations in this cohort have not appeared on the schedule. Posterior means with 90% credible intervals from our Bayesian pathway model; segment-level odds by technology, disease area and first-in-class status are in the subscription.
The pathway, step by step
Registration: the TGA, in parallel if you choose
The TGA registers the medicine; the parallel process lets the PBAC submission run alongside registration rather than after it, compressing time-to-listing by many months for confident assets.
Engage: choose parallel TGA, PBAC lodgement deliberately; it trades risk for speedPBAC submission: against the replaced therapy
Submissions land in one of three annual cycles. The comparator rule is practical, not flattering: the therapy most likely to be replaced in practice, often the cheapest relevant alternative in a reference-priced formulary. Economic evaluation (cost-effectiveness or cost-minimisation) plus DUSC-scrutinised utilisation estimates carry the case.
Engage: pre-submission advice; ESC and DUSC will test methods and volumesPBAC outcome: recommend, reject or defer
Outcomes publish openly. The distinctive feature is what happens after a negative: resubmissions are institutionalised, deferred items usually convert, and rejected molecules return with sharper offers. Our data shows 42% of them eventually get recommended.
Our data: 69% recommended · deferral→yes 63% · rejection→eventual yes 42%Pricing and listing mechanics
Pricing negotiation with the department follows the recommendation, inside the statutory machinery: reference pricing within therapeutic groups, risk-sharing deeds and caps where volumes are uncertain, and Cabinet sign-off for high-cost listings (above ~$20m/year). Special Arrangements (s100) carry hospital-administered and specialised medicines.
Engage: risk-share design: caps and rebates are where uncertain forecasts get settledStatutory reductions and price disclosure
Listing is not the end of pricing. Anniversary reductions, F1→F2 movement on generic entry and price disclosure, reimbursement chasing real market prices down, keep working on your price. Our apixaban data shows the signature: a 25% disclosure-driven cut in one step, years after listing.
Our data: apixaban PBS price fell ~25% in one disclosure cycle (Aug 2024)What the record actually shows
Who decides what, and when to engage
| Institution | What it decides | Evidence it weighs | When to engage |
|---|---|---|---|
| TGA Regulator | Registration and label | Efficacy, safety, quality | Early; decide on parallel process at planning stage |
| PBAC Advisory committee | Whether to recommend PBS listing, the effective gate | Cost-effectiveness vs the replaced therapy; clinical need; financial estimates | Pre-submission advice; fixed lodgement windows; resubmission strategy |
| ESC & DUSC PBAC subcommittees | Methods scrutiny and utilisation estimates | Model validity; realistic uptake volumes | Through submission quality; they read everything |
| Department of Health / PBS pricing Payer | Negotiated price, deeds, risk-share terms | Reference prices, volumes, caps | Post-recommendation, with deed terms modelled in advance |
| Cabinet Government | Sign-off for high-cost listings (≳ $20m/yr) | Fiscal impact | Indirectly; build the case for the department to carry |
| States & hospitals Delivery | s100 arrangements, hospital access | Service fit | For specialised/hospital-administered medicines |
The evidence Australia actually asks for
The replaced therapy, honestly chosen. The comparator is what prescribers would actually stop using. In a reference-priced system it is, often inexpensive. Comparator optimism is the most common first-submission wound.
Utilisation estimates that survive DUSC. Financial estimates are examined as hard as the clinical case; optimistic uptake curves cost credibility and invite caps.
A resubmission plan from day one. With 42% of rejections eventually converting, the rational strategy treats the first submission as the opening bid and pre-plans the evidence and price moves for round two.
Lifecycle price modelling. Statutory reductions and price disclosure are forecastable: build them in, as our PBS price data makes visible molecule by molecule.
Where companies get hurt
Planning an Australian launch?
We build PBAC-ready economic cases, DUSC-proof utilisation estimates and resubmission strategy, grounded in the same outcome record you can check on this site. Fixed fees, senior-built.
Talk to us